BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32948832)

  • 1. miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer.
    Palma F; Affinito A; Nuzzo S; Roscigno G; Scognamiglio I; Ingenito F; Martinez L; Franzese M; Zanfardino M; Soricelli A; Fiorelli A; Condorelli G; Quintavalle C
    Cancer Gene Ther; 2021 May; 28(5):413-426. PubMed ID: 32948832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway.
    Zhou YL; Xu YJ; Qiao CW
    Int J Clin Exp Pathol; 2015; 8(6):6312-22. PubMed ID: 26261507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS.
    Fan Q; Hu X; Zhang H; Wang S; Zhang H; You C; Zhang CY; Liang H; Chen X; Ba Y
    Cell Physiol Biochem; 2017; 44(4):1311-1324. PubMed ID: 29183007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer.
    Liu F; Wang X; Li J; Gu K; Lv L; Zhang S; Che D; Cao J; Jin S; Yu Y
    Cell Prolif; 2015 Oct; 48(5):582-92. PubMed ID: 26250586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in
    Fanini F; Bandini E; Plousiou M; Carloni S; Wise P; Neviani P; Murtadha M; Foca F; Fabbri F; Vannini I; Fabbri M
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-222-3p Promotes Cell Proliferation and Inhibits Apoptosis by Targeting PUMA (BBC3) in Non-Small Cell Lung Cancer.
    Chen W; Li X
    Technol Cancer Res Treat; 2020; 19():1533033820922558. PubMed ID: 32588752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomes with low miR-34c-3p expression promote invasion and migration of non-small cell lung cancer by upregulating integrin α2β1.
    Huang W; Yan Y; Liu Y; Lin M; Ma J; Zhang W; Dai J; Li J; Guo Q; Chen H; Makabel B; Liu H; Su C; Bi H; Zhang J
    Signal Transduct Target Ther; 2020 Apr; 5(1):39. PubMed ID: 32317629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism.
    Cui J; Xu F; Bai W; Zhao T; Hong J; Zuo W
    J Transl Med; 2023 Feb; 21(1):125. PubMed ID: 36793108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
    Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
    Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA SNHG6 promotes the growth and invasion of non-small cell lung cancer by downregulating miR-101-3p.
    Li K; Jiang Y; Xiang X; Gong Q; Zhou C; Zhang L; Ma Q; Zhuang L
    Thorac Cancer; 2020 May; 11(5):1180-1190. PubMed ID: 32147945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA SNHG1 influences cell proliferation, migration, invasion, and apoptosis of non-small cell lung cancer cells via the miR-361-3p/FRAT1 axis.
    Li X; Zheng H
    Thorac Cancer; 2020 Feb; 11(2):295-304. PubMed ID: 31788970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2.
    Ma J; Miao H; Zhang H; Ren J; Qu S; Da J; Xu F; Zhao H
    Diagn Pathol; 2021 May; 16(1):46. PubMed ID: 34022918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.
    Yu L; Chen D; Song J
    Thorac Cancer; 2020 Mar; 11(3):603-611. PubMed ID: 31953899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. microRNA-100 functions as a tumor suppressor in non-small cell lung cancer via regulating epithelial-mesenchymal transition and Wnt/β-catenin by targeting HOXA1.
    Han W; Ren X; Yang Y; Li H; Zhao L; Lin Z
    Thorac Cancer; 2020 Jun; 11(6):1679-1688. PubMed ID: 32364673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6.
    Sun C; Li S; Yang C; Xi Y; Wang L; Zhang F; Li D
    Biochem Biophys Res Commun; 2016 Feb; 471(1):82-8. PubMed ID: 26845350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
    Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
    J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.